Positive visual phenomena following implantation of the argus II retinal prosthesis

Ama Sadaka; Cyrus Iqbal; Hossein Nazari; Shauna Berry; Charles C. Wykoff; Mark S. Humayun; Andrew G. Lee

doi:10.3928/23258160-20171130-11

Positive visual phenomena following implantation of the argus II retinal prosthesis

Ama Sadaka, Cyrus Iqbal, Hossein Nazari, Shauna Berry, Charles C. Wykoff, Mark S. Humayun, Andrew G. Lee

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 62-year-old female who was legally blind secondary to retinitis pigmentosa (RP) developed new positive visual phenomena (PVP) ("visual storms") following implantation of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, CA). The potential mechanisms for the exacerbating PVP or hallucinatory release phenomena are proposed. Clinicians should be aware of these visual phenomena in patients with RP and the potential for worsening of or de novo development of PVP in patients considering the Argus II implant.

Original language	English (US)
Pages (from-to)	1022-1025
Number of pages	4
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	48
Issue number	12
DOIs	https://doi.org/10.3928/23258160-20171130-11
State	Published - Dec 2017
Externally published	Yes

Bibliographical note

Funding Information:
Originally submitted February 12, 2017. Revision received May 9, 2017. Accepted for publication August 2, 2017. Disclosures: Dr. Wykoff has received grants from Adverum Biotechnologies, Aerpio Therapeutics, Allegro Ophthalmics, Aldeyra Therapeutics, Apellis Pharmaceutical, Astellas Pharma, Aura Biosciences, Boehringer-Ingelheim, Chiltern International, GlaxoSmithKline, Heidelberg Engineering, Iconic Therapeutics, INC Research, Johns Hopkins University, NEI, Novartis International AG, OHR Pharmaceutical, Ophthotech Corporation, Ora, pSivida Corp., Regenxbio, SciFluor Life Sciences, Taiwan Liposome Company, Tyro-genex; grants and personal fees from Alcon Laboratories, Allergan, Clear-side Biomedical, Genentech, Regeneron Pharmaceuticals, Roche Holding AG, and Santen; and personal fees from Alimera Sciences, Alnylam Pharmaceuticals, Atheneum Partners, Bayer AG, Consultants LLC, CORCEPT, Destum Partners, D.O.R.C. International, Hexal AG, k2c Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, PRIME Education, System Analytic, ThromboGenics NV, and Valeant Pharmaceuticals International outside the submitted work. Dr. Humayun is a speaker, consultant, and stockholder and has a patent issued for Second Sight Medical Products. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist Hospital, 6560 Fannin Street, Suite 450, Houston, TX 77030; email: [email protected]. doi: 10.3928/23258160-20171130-11

Publisher link

10.3928/23258160-20171130-11

Find It

Find It at U of M Libraries

Cite this

@article{15b048d4cc3f429a8c77023fd6469a06,

title = "Positive visual phenomena following implantation of the argus II retinal prosthesis",

abstract = "A 62-year-old female who was legally blind secondary to retinitis pigmentosa (RP) developed new positive visual phenomena (PVP) ({"}visual storms{"}) following implantation of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, CA). The potential mechanisms for the exacerbating PVP or hallucinatory release phenomena are proposed. Clinicians should be aware of these visual phenomena in patients with RP and the potential for worsening of or de novo development of PVP in patients considering the Argus II implant.",

author = "Ama Sadaka and Cyrus Iqbal and Hossein Nazari and Shauna Berry and Wykoff, {Charles C.} and Humayun, {Mark S.} and Lee, {Andrew G.}",

note = "Funding Information: Originally submitted February 12, 2017. Revision received May 9, 2017. Accepted for publication August 2, 2017. Disclosures: Dr. Wykoff has received grants from Adverum Biotechnologies, Aerpio Therapeutics, Allegro Ophthalmics, Aldeyra Therapeutics, Apellis Pharmaceutical, Astellas Pharma, Aura Biosciences, Boehringer-Ingelheim, Chiltern International, GlaxoSmithKline, Heidelberg Engineering, Iconic Therapeutics, INC Research, Johns Hopkins University, NEI, Novartis International AG, OHR Pharmaceutical, Ophthotech Corporation, Ora, pSivida Corp., Regenxbio, SciFluor Life Sciences, Taiwan Liposome Company, Tyro-genex; grants and personal fees from Alcon Laboratories, Allergan, Clear-side Biomedical, Genentech, Regeneron Pharmaceuticals, Roche Holding AG, and Santen; and personal fees from Alimera Sciences, Alnylam Pharmaceuticals, Atheneum Partners, Bayer AG, Consultants LLC, CORCEPT, Destum Partners, D.O.R.C. International, Hexal AG, k2c Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, PRIME Education, System Analytic, ThromboGenics NV, and Valeant Pharmaceuticals International outside the submitted work. Dr. Humayun is a speaker, consultant, and stockholder and has a patent issued for Second Sight Medical Products. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist Hospital, 6560 Fannin Street, Suite 450, Houston, TX 77030; email: [email protected]. doi: 10.3928/23258160-20171130-11",

year = "2017",

month = dec,

doi = "10.3928/23258160-20171130-11",

language = "English (US)",

volume = "48",

pages = "1022--1025",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "12",

}

TY - JOUR

T1 - Positive visual phenomena following implantation of the argus II retinal prosthesis

AU - Sadaka, Ama

AU - Iqbal, Cyrus

AU - Nazari, Hossein

AU - Berry, Shauna

AU - Wykoff, Charles C.

AU - Humayun, Mark S.

AU - Lee, Andrew G.

N1 - Funding Information: Originally submitted February 12, 2017. Revision received May 9, 2017. Accepted for publication August 2, 2017. Disclosures: Dr. Wykoff has received grants from Adverum Biotechnologies, Aerpio Therapeutics, Allegro Ophthalmics, Aldeyra Therapeutics, Apellis Pharmaceutical, Astellas Pharma, Aura Biosciences, Boehringer-Ingelheim, Chiltern International, GlaxoSmithKline, Heidelberg Engineering, Iconic Therapeutics, INC Research, Johns Hopkins University, NEI, Novartis International AG, OHR Pharmaceutical, Ophthotech Corporation, Ora, pSivida Corp., Regenxbio, SciFluor Life Sciences, Taiwan Liposome Company, Tyro-genex; grants and personal fees from Alcon Laboratories, Allergan, Clear-side Biomedical, Genentech, Regeneron Pharmaceuticals, Roche Holding AG, and Santen; and personal fees from Alimera Sciences, Alnylam Pharmaceuticals, Atheneum Partners, Bayer AG, Consultants LLC, CORCEPT, Destum Partners, D.O.R.C. International, Hexal AG, k2c Medical Communications, Notal Vision, Novo Nordisk, ONL Therapeutics, PRIME Education, System Analytic, ThromboGenics NV, and Valeant Pharmaceuticals International outside the submitted work. Dr. Humayun is a speaker, consultant, and stockholder and has a patent issued for Second Sight Medical Products. The remaining authors report no relevant financial disclosures. Address correspondence to Andrew G. Lee, MD, Blanton Eye Institute, Houston Methodist Hospital, 6560 Fannin Street, Suite 450, Houston, TX 77030; email: [email protected]. doi: 10.3928/23258160-20171130-11

PY - 2017/12

Y1 - 2017/12

N2 - A 62-year-old female who was legally blind secondary to retinitis pigmentosa (RP) developed new positive visual phenomena (PVP) ("visual storms") following implantation of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, CA). The potential mechanisms for the exacerbating PVP or hallucinatory release phenomena are proposed. Clinicians should be aware of these visual phenomena in patients with RP and the potential for worsening of or de novo development of PVP in patients considering the Argus II implant.

AB - A 62-year-old female who was legally blind secondary to retinitis pigmentosa (RP) developed new positive visual phenomena (PVP) ("visual storms") following implantation of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, CA). The potential mechanisms for the exacerbating PVP or hallucinatory release phenomena are proposed. Clinicians should be aware of these visual phenomena in patients with RP and the potential for worsening of or de novo development of PVP in patients considering the Argus II implant.

UR - http://www.scopus.com/inward/record.url?scp=85039036672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039036672&partnerID=8YFLogxK

U2 - 10.3928/23258160-20171130-11

DO - 10.3928/23258160-20171130-11

M3 - Article

C2 - 29253307

AN - SCOPUS:85039036672

SN - 2325-8160

VL - 48

SP - 1022

EP - 1025

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 12

ER -

Positive visual phenomena following implantation of the argus II retinal prosthesis

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this